What pharmacologic options can be utilized to decrease heart rate in supraventricular tachycardia?

What pharmacologic options can be utilized to decrease heart rate in supraventricular tachycardia?

• A. Beta blockers and calcium channel blockers
• B. ACE inhibitors and diuretics
• C. Antibiotics and analgesics
• D. Anticoagulants and antiplatelet agents

Answer: (A)

The correct answer is centered on the role of beta blockers and calcium channel blockers in managing supraventricular tachycardia (SVT). Both of these classes of medications are effective at decreasing heart rate by influencing the electrical conduction system of the heart. Beta blockers work by antagonizing the effects of catecholamines, such as adrenaline, which can increase heart rate and myocardial contractility. This reduction in sympathetic stimulation helps to slow down the heart rate, making them particularly useful in conditions like SVT. Calcium channel blockers also contribute to heart rate control by inhibiting the influx of calcium into cardiac muscle cells. This action leads to reduced automaticity in the atrial tissue, and slower conduction through the AV node, both of which are vital in managing SVT. Other choices, such as ACE inhibitors and diuretics, primarily target blood pressure control and fluid management rather than directly influencing heart rate in the context of SVT. Antibiotics and analgesics are not relevant, as they are geared toward treating infections and pain, respectively, not arrhythmias. Anticoagulants and antiplatelet agents are used to prevent thromboembolic events, which can occur as a complication of certain arrhythmias but do not affect heart rate

The correct answer is centered on the role of beta blockers and calcium channel blockers in managing supraventricular tachycardia (SVT). Both of these classes of medications are effective at decreasing heart rate by influencing the electrical conduction system of the heart.

Beta blockers work by antagonizing the effects of catecholamines, such as adrenaline, which can increase heart rate and myocardial contractility. This reduction in sympathetic stimulation helps to slow down the heart rate, making them particularly useful in conditions like SVT.

Calcium channel blockers also contribute to heart rate control by inhibiting the influx of calcium into cardiac muscle cells. This action leads to reduced automaticity in the atrial tissue, and slower conduction through the AV node, both of which are vital in managing SVT.

Other choices, such as ACE inhibitors and diuretics, primarily target blood pressure control and fluid management rather than directly influencing heart rate in the context of SVT. Antibiotics and analgesics are not relevant, as they are geared toward treating infections and pain, respectively, not arrhythmias. Anticoagulants and antiplatelet agents are used to prevent thromboembolic events, which can occur as a complication of certain arrhythmias but do not affect heart rate